Pharma R&D Today

Is the Pharma Industry Missing the Big Picture?

Posted on September 22nd, 2017 by Christine de Vries - Scheidegger

There is a disconnect between how drugs are developed and how they are used. In the traditional method of target-oriented development, each new candidate drug is scrutinized in a handful of interactions with desirable and undesirable targets. Continue reading “Is the Pharma Industry Missing the Big Picture?” »

Big Data and Proactive Pharmacovigilance

Posted on September 20th, 2017 by Christy J. Wilson

Traditionally thought of as a post-market process, pharmacovigilance is how pharmaceutical companies monitor and address any safety issues that arise once a drug becomes available commercially. However, some companies are now thinking ahead about these potential safety concerns with what is known as “proactive PV”. Continue reading “Big Data and Proactive Pharmacovigilance” »

Artificial Intelligence Comes to the Life Sciences

Posted on September 18th, 2017 by Betsy Davis

Advances in neural network technology are making it possible to ‘teach’ machines more rapidly—and this machine learning can have big implications for the healthcare and life sciences industry. Continue reading “Artificial Intelligence Comes to the Life Sciences” »

The Challenges of Signal Detection in Spontaneous Reporting

Posted on September 13th, 2017 by Sherry Winter

Pharmacovigilance is essential to pharmaceutical businesses. It facilitates the correct use of a drug, safeguarding the drug as a meaningful treatment option when the benefits it offers outweigh known risks, or measures can be taken to mitigate those risks. Continue reading “The Challenges of Signal Detection in Spontaneous Reporting” »

Taking a Balanced Approach to Monitoring Literature

Posted on September 11th, 2017 by Neal Katz

In a time when the focus on pharmacovigilance is greater than ever before, literature monitoring presents pharmaceutical companies with significant challenges. Pharmacovigilance groups are looking for ways to efficiently and cost-effectively manage an increasing workload while remaining compliant with regulatory best practices. Continue reading “Taking a Balanced Approach to Monitoring Literature” »

Harnessing the Power of Content in Scientific Research

Posted on September 11th, 2017 by Patricia Morgan

Biological research today can be summarized in one word — data.

Massive quantities of information are generated daily from large and small laboratories, individuals, universities, and commercial organizations. Continue reading “Harnessing the Power of Content in Scientific Research” »

About this Blog

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.